Introduction {#s2}
============

Three randomized trials in South Africa [@pmed.1000187-Auvert1], Kenya [@pmed.1000187-Bailey1], and Uganda [@pmed.1000187-Gray1] found that male circumcision (MC) reduces the risk of HIV acquisition in men, a finding supported by prior observational studies [@pmed.1000187-Weiss1]. The foreskin is rich in HIV target cells and the inner preputial mucosa is thought to be lightly keratinized and vulnerable to HIV infection [@pmed.1000187-Szabo1]--[@pmed.1000187-Donoval1]. Thus, it is hypothesized that circumcision may reduce HIV infection by removal of this vulnerable tissue. The Ugandan trial also found that circumcision decreased the rate of self-reported genital ulcer disease (GUD) [@pmed.1000187-Gray1] and the incidence of herpes simplex virus type 2 (HSV-2) [@pmed.1000187-Tobian1]; these findings had previously been suggested by observational studies [@pmed.1000187-Weiss2]. The South African trial reported that circumcision was equally protective against HIV acquisition in HSV-2 seropositive and seronegative men [@pmed.1000187-SobngwiTambekou1]. GUD, particularly due to HSV-2, is thought to be a cofactor for HIV acquisition [@pmed.1000187-Rottingen1]--[@pmed.1000187-Corey1]. Thus it is possible that circumcision prevents HIV in part by reducing genital ulceration and HSV-2.

We conducted a secondary data analysis from the randomized trials of MC for HIV prevention in Rakai, Uganda, to assess the degree to which circumcision-related reductions in symptomatic genital ulcers and HSV-2 potentially mediated the effect of MC on HIV prevention.

Methods {#s3}
=======

We conducted two concurrent randomized trials that enrolled consenting uncircumcised men aged 15--49 y and randomized them to receive immediate circumcision (intervention arm), or circumcision delayed for 24 mo (control arm) ([Text S3](#pmed.1000187.s003){ref-type="supplementary-material"}). Details have been published previously [@pmed.1000187-Gray1],[@pmed.1000187-Tobian1]. Participants provided written informed consent for screening, enrollment, and follow up, and men receiving circumcision also provided written consent for surgery. Participants were followed at 6, 12, and 24 mo and interviewed with regard to sexual risk behaviors and self-reported genital ulceration during the preceding follow-up interval, as well as recent GUD symptoms within 1 wk of the study visit. In addition, a genital exam was performed and swabs taken from any observed penile lesion. One trial supported by the National Institutes of Health (NIH) enrolled HIV-negative men who, as condition for enrollment eligibility, accepted voluntary counseling and testing (VCT) and agreed to learn their HIV results. A second trial, supported by the Bill & Melinda Gates Foundation, enrolled HIV-negative men who accepted pre-test counseling but declined to learn their HIV results, and thus were ineligible for enrollment in the NIH trial. Under Ugandan policy persons may provide blood for testing but decline to learn their test result, and such individuals were not denied access to trial participation. All participants were offered intensive HIV prevention education, access to free HIV VCT, and condoms, provided free of charge, and were strongly encouraged at each study visit to practice safe sex behaviors and to avail themselves of VCT and condoms. The trials are registered with ClinicalTrials.gov numbers NCT00425984 for NIH trial and NCT00124878 for the Gates Foundation trial. The protocol (see [Text S1](#pmed.1000187.s001){ref-type="supplementary-material"} and [Text S2](#pmed.1000187.s002){ref-type="supplementary-material"}) was reviewed and approved by the Uganda National Council for Science and Technology, and by three Institutional Review Boards (IRBs): the Science and Ethics Committee of the Uganda Virus Research Institute, Entebbe, Uganda; the Committee for Human Research at Johns Hopkins University, Bloomberg School of Public Health; and the Western Institutional Review Board, Olympia, Washington. The data were analyzed without personal identifiers.

The objective of this analysis was to assess the degree to which GUD and HSV-2 serostatus contributed to the reduced HIV incidence observed in circumcised men. This analysis used data from all initially HIV-uninfected men enrolled in either trial who contributed follow-up time for determination of incident HIV infection, and for whom we had HSV-2 serology at enrollment and follow up. The trial profile is given in [Figure 1](#pmed-1000187-g001){ref-type="fig"}. 6,396 men were screened of whom 5,534 HIV-negative men were enrolled. There were a total of 2,756 HIV-negative men enrolled in the intervention arm of either trial and 2,775 men enrolled in the control arm of either trial available for this analysis. Of these enrolled participants, 2,319 intervention arm (84.1%) and 2,339 control arm (84.3%) were followed over 2 y.

![Trial profile.](pmed.1000187.g001){#pmed-1000187-g001}

The enrollment blood samples for these men were tested for HSV-2 antibodies using the HSV-2 ELISA (Kalon Biological Ltd.). On the basis of prior evaluation of test performance in Ugandan sera using HSV-2 University of Washington Western blot as the gold standard, HSV-2 positive status was defined as a Kalon ELISA index value of ≥1.5 [@pmed.1000187-Gamiel1]. Men with a Kalon index value ≤0.9 were classified as HSV-2 negative. Trial enrollment samples with Kalon index values between 0.90--1.49 were classified as indeterminate HSV-2 status. Only HSV-2 negative individuals were evaluated for HSV-2 seroconversion (index value ≥1.5). All seroconversions were confirmed by Euroimmun Western blot (Euroimmun). HSV-2 serostatus was classified into four mutually exclusive groups; HSV-2 positive at enrollment, HSV-2 indeterminate at enrollment, HSV-2 seronegative at enrollment and throughout follow up, and HSV-2 seroconversions. HIV status was determined by two separate ELISAs and confirmed by HIV-1 Western blot, as previously described [@pmed.1000187-Gray1]. Serologic syphilis was assessed at each study visit on the basis of a positive rapid plasma reagin (RPR) (Becton Dickinson) or toluidine red unheated serum test (TRUST) (New Horizons Diagnostics Corporation) and confirmed by a positive *Treponema pallidum* particle agglutination assay (TPPA) (Serodia-TP PA kit, Fujirebio Inc.).

For men who had a genital lesion observed at the time of a study visit, a swab was obtained for detection of *Haemophilus ducreyi*, *T. pallidum*, HSV-1, and HSV-2 using real-time multiplex PCR [@pmed.1000187-Barros1]--[@pmed.1000187-Orle1]. Two multiplex real-time PCR reactions using fluorescent probes for two pathogens in a single reaction (*H. ducreyi* and *T. pallidum* or HSV-1 and HSV-2), were performed on extracted DNA. Samples were run in duplicate, and discordant results were repeated in a single-pathogen real-time PCR reaction.

Statistical Analysis {#s2a}
--------------------

Enrollment sociodemographic and behavioral characteristics of intervention and control arm participants, and the characteristics of HSV-2 seropositive and seronegative men were compared. Differences between groups were assessed using Chi-square tests. At each study visit, we assessed the frequency of self-reported GUD during the preceding follow-up interval to estimate the period prevalence of GUD per 100 follow-up visits. Prevalence risk ratios (PRRs) and 95% confidence intervals (95% CI) estimated by modified Poisson regression [@pmed.1000187-Barros1] were used to assess differences in GUD frequency between study arms and strata of HSV-2 status. Because men could report multiple episodes of symptomatic ulceration in different follow-up intervals, robust variance estimates based on generalized estimating equations were used to account for within-individual correlation. We also assessed the point prevalence of GUD observed at the time of a study visit and the proportion of ulcer swabs with sexually transmitted infection (STI) pathogens detected by real-time PCR.

We determined HIV acquisition during each follow-up interval and cumulated interval-specific incident HIV events and person time over the period of observation. There were a total of 105 incident HIV infections, 36 in the intervention arm and 69 in the control arm participants. HIV incidence rates were estimated per 100 person years (py) assuming that infection occurred midway between the last HIV-negative and first HIV-positive serologic test. Differences in HIV incidence between study arms, stratified by HSV-2 status and GUD symptoms were assessed by incidence rate ratios (IRRs) and 95% CI estimated by Poisson multiple regression after adjustment for covariates found to be significantly associated with HIV acquisition in univariate analyses at *p*\<0.15. The covariates used in adjusted models included age, marital status, number of sex partners, and condom use. Exact 95% CI were estimated if any cell contained less than five observations.

We hypothesized that GUD and incident HSV-2 could be intermediate factors between circumcision and HIV acquisition, because both are reduced by circumcision and are related to incident HIV. Therefore, we conducted a mediation analysis using two logistic regression models, one estimating the net effect of circumcision on HIV incidence without adjustment for the intermediate variables, and the second model estimating the direct effects of circumcision on HIV acquisition after adjustment for potential mediating variables (GUD or incident HSV-2) [@pmed.1000187-Freedman1]. We then estimated the proportion of the circumcision effect on HIV acquisition explained by the effects of circumcision on intermediate variables using the expression , where is the coefficient estimate of the circumcision effect from the model including the intermediate variable, and is the coefficient from the model without the intermediate variable. The confidence interval for *p* was obtained using bias corrected and accelerated (BCa) bootstrap confidence intervals. Specifically, since the incidence of HIV was rare, we used a stratified bootstrap method by bootstrapping in the HIV incidence samples and nonincidence samples, respectively. All the analyses were performed in R 2.8.1 environment. The whole trial population was assessed for the mediating effect of GUD, since circumcision was found to reduce GUD, irrespective of HSV-2 serostatus. To assess the mediating effect on incident HSV-2 infection, the population was restricted to men who were HSV-2 negative at enrollment and thus at risk of HSV-2 seroconversion during follow up.

We also estimated the attributable risk (AR) of incident HIV associated with GUD or HSV-2 using the formula [@pmed.1000187-Jewell1], where exposure is GUD or HSV-2 seroconversion, respectively. The standard errors of the AR were estimated from log () for 95% CI calculations. ARs of HIV acquisition associated with GUD or HSV-2 were estimated separately by study arm. To test the null hypothesis that the AR associated with GUD or HSV-2 is the same between study arms, the *p*-value for the difference in AR between arms was calculated by comparing the approximated normal distributions of log () for the two arms.

Results {#s4}
=======

[Table 1](#pmed-1000187-t001){ref-type="table"} shows the distribution of participant characteristics at enrollment. HSV-2 prevalence was 28.3% (782/2,576) in the intervention arm and 27.4% (759/2,775) in the control arm. HSV-2 indeterminate serostatus (Kalon Elisa index values 1.0 to 1.49) was similar in intervention (10.1%, 278/2,756) and control arms (10.8%, 299/2,775), and 61.5% of intervention arm men (1696/2,756) versus 61.7% of control arm men (1,717/2,775) were HSV-seronegative at enrollment. The two study arms were also comparable with respect to sociodemographic and behavioral characteristics ([Table 1](#pmed-1000187-t001){ref-type="table"}). However, there were marked differences in the characteristics of men who were HSV-2 seropositive and seronegative at enrollment. Compared to HSV-2 negative men, HSV-2-positive men were significantly older (40+ y, 13.9% versus 2.6%, χ^2^ *p*\<0.0001), more likely to be currently or previously married (77.2% versus 42.5%, χ^2^ *p*\<0.0001), to have a higher number of reported sex partners in the past year (2+ 43.8% versus 31.8%, χ^2^ *p*\<0.0001), and were less likely to consistently use condoms (7.9% versus 16.9%, χ^2^ *p*\<0.0001).

10.1371/journal.pmed.1000187.t001

###### Characteristics of the study populations at enrollment.
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                                   Enrollment HSV-2 Positive   Enrollment HSV-2 Negative   All Participants                                                                  
  ------------------------------- --------------------------- --------------------------- ------------------ ------- ------- ------- ------- ------- ------- ------- ------- -------
  **All**                                     782                        100.0                   759          100.0   1,696   100.0   1,717   100.0   2,756   100.0   2,775   100.0
  **Age (y)**                                                                                                                                                                
  **15--29**                                  412                        52.7                    389          51.2    1,379   81.3    1,430   83.2    1,988   72.1    2,037   73.4
  **30--39**                                  267                        34.1                    261          34.3     269    15.9     247    14.4     598    21.7     575    20.7
  **40+**                                     103                        13.2                    110          14.5     48      2.8     41      2.4     170     6.2     163     5.9
  **Marital status**                                                                                                                                                         
  **Currently married**                       534                        68.3                    519          68.4     658    38.8     654    38.1    1,340   48.6    1,332   48.0
  **Previously married**                      65                          8.3                     71           9.4     82      4.8     56      3.3     165     6.0     141     5.1
  **Never married**                           183                        23.4                    169          22.3     956    56.4    1,007   58.7    1,251   45.4    1,302   46.9
  **Sex partners in past year**                                                                                                                                              
  **None**                                    74                          9.5                     63           8.3     363    21.4     402    23.4     493    17.9     518    18.7
  **One**                                     368                        47.1                    362          47.7     786    46.3     776    45.2    1,288   46.7    1,279   46.1
  **Two**                                     219                        28.0                    237          31.2     348    20.5     367    21.4     621    22.5     670    24.1
  **Three or more**                           121                        15.5                     97          12.8     199    11.7     172    10.0     354    12.8     308    11.1
  **Condom use**                                                                                                                                                             
  **None**                                    469                        60.0                    436          57.4     942    55.5     957    55.7    1,589   57.7    1,564   57.7
  **Inconsistent**                            254                        32.5                    261          34.4     466    27.5     474    27.6     791    28.7     826    29.8
  **Consistent**                              59                          7.5                     62           8.2     288    17.0     286    16.7     376    13.6     385    13.9

As shown in [Table 2](#pmed-1000187-t002){ref-type="table"}, the period prevalence of self-reported GUD per 100 study visits was significantly lower in the intervention than the control arm men (PRR 0.59, 95% CI 0.50--0.69, Wald test, *p*\<0.0001). In a multivariate model, adjusted for age, number of sexual partners, and condom use, the PRR of GUD associated with circumcision was 0.54 (95% CI 0.44--0.66). Other covariates significantly associated with lower symptomatic GUD were having no sex partners during the follow-up interval (PRR = 0.26, 95% CI 0.16--0.42) and consistent condom use (PRR = 0.63, 95% CI 0.43--0.92). The prevalence of self-reported GUD was significantly lower in the intervention than the control arm irrespective of HSV-2 status at enrollment or HSV-2 acquisition during follow up, although the highest rates of symptomatic GUD were reported among men who seroconverted to HSV-2 during the trial.

10.1371/journal.pmed.1000187.t002

###### Self reported genital ulceration by enrollment HSV-2 status and study arm.
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                                   Intervention   Control                     
  ------------------------------- -------------- --------- ----------- ------ -------------------
  **All**                           212/7,332       2.9     361/7,353   4.9    0.59 (0.50--0.69)
  **HSV-2 Status**                                                            
  **HSV-2 positive**                 91/2,111       4.3     134/2,056   6.5    0.66 (0.51--0.84)
  **HSV-2 indeterminate**             29/753        3.9      48/785     6.1    0.63 (0.41--0.96)
  **HSV-2 seroconverters**            18/336        5.4      50/452     11.1   0.48 (0.30--0.79)
  **Persistent HSV-2 negative**      74/4,132       1.8     129/4,060   3.2    0.51 (0.43--0.74)

The point prevalence of clinically observed GUD reported at the time of a study visit was 0.8% in the intervention arm (53/6,554 visits) and 1.9% (121/6,544 visits) in the control arm (PRR = 0.44, 95% CI 0.32--0.61). Swabs for multiplex PCR were obtained from visible lesions in 25 symptomatic intervention arm men and 56 symptomatic control arm men. HSV-2 was detected in 48.0% (12/25) of GUD swabs assayed among symptomatic circumcised men, and 39.4% (22/56) of swabs assayed for symptomatic uncircumcised men (χ^2^ *p* = 0.62). No *T. pallidum* was detected by PCR in intervention arm men, whereas seven *T. pallidum* infections were found among control arm participants (9.6%, χ^2^ *p* = 0.09). No cases of ulcers due to *H. ducreyi* or HSV-1 were detected in either study arm. It is noteworthy that of those symptomatic participants tested by PCR, no STI pathogen was detected in 52.0% of 25 intervention arm men and 60.7% of 56 control arm men, suggesting that many observed lesions did not have an STI etiology.

There were 202 intervention arm men and 195 control arm men with positive syphilis serology during follow-up visits. Among these individuals, GUD symptoms were reported during the follow-up interval preceding serologic syphilis detection in 4.5% of visits by intervention arm men (9/202), and in 13.3% of visits in by control arm men (26/195, PRR = 0.33, 95% CI 0.16--0.69, χ^2^ *p* = 0.003). Among men who were *T. pallidum* seronegative throughout the study, the frequency of GUD symptoms was 3.2% (226/7,942 visits) in intervention arm men and 5.8% (413/7,095 visits) in control arm men (PRR = 0.55, 95% CI 0.47--0.65).

HIV incidence is shown in [Table 3](#pmed-1000187-t003){ref-type="table"}. HIV incidence was 0.78/100 py among circumcised men and 1.44/100 py among uncircumcised men (IRR = 0.54, 95% CI 0.35--0.78). HIV incidence was lower in circumcised than in uncircumcised men with self-reported symptomatic GUD (IRR = 0.55, 95% CI 0.20--1.50), although this difference was not statistically significant. However, circumcision was significantly protective against HIV acquisition in men without GUD symptoms (IRR = 0.57, 95% CI 0.37--0.89). We did not observe a reduction in the risk of HIV acquisition among men who were HSV-2 positive at enrollment (IRR = 0.89, 95% CI 0.49--1.60), irrespective of whether the prevalent HSV-2 positive men reported GUD symptoms (IRR = 0.92, 95% CI 0.15--4.90) or were asymptomatic (IRR = 0.94, 95% CI 0.49--1.81). The interaction between HSV-2 seropositive status and treatment arm was not statistically significant (likelihood ratio *p* = 0.07).

10.1371/journal.pmed.1000187.t003

###### HIV incidence by self-reported GUD and HSV-2 status and study arm.
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                              Intervention   Control                      
  -------------------------- -------------- --------- ------------ ------ -------------------
  **All**                      36/4,825.5     0.78     69/4,846.0   1.44   0.54 (0.35--0.78)
  **GUD symptoms**               5/173        2.89      16/303.5    5.27   0.55 (0.20--1.50)
  **No GUD**                   31/4,652.5     0.70     53/4,542.5   1.18   0.57 (0.37--0.89)
  **HSV-2 positive**                                                      
  **All**                       21/1,392      1.51     23/1,358.5   1.69   0.89 (0.49--1.60)
  **GUD symptoms**                3/74         4.1      5/117.5     4.26   0.92 (0.15--4.90)
  **No GUD**                    18/1,318      1.37      18/1,241    1.45   0.94 (0.49--1.81)
  **HSV-2 indeterminate**                                                 
  **All**                        3/501        0.60       14/519     2.70   0.22 (0.04--0.80)
  **GUD symptoms**                1/25        4.00        3/44      6.82   0.59 (0.01--7.31)
  **No GUD**                     2/476        0.83       11/475     2.32   0.18 (0.02--0.83)
  **HSV-2 seroconverters**                                                
  **All**                        5/221        2.26      12/296.5    4.05   0.56 (0.19--1.57)
  **GUD symptoms**               1/15.5       6.45       4/40.5     9.88   0.65 (0.01--6.60)
  **No GUD**                    4/205.5       1.95       8/256      3.13   0.62 (0.14--2.32)
  **HSV-2 negative**                                                      
  **All**                      7/2,711.5      0.26      20/2,672    0.77   0.34 (0.15--0.81)
  **GUD symptoms**               0/58.5         0       4/101.5     3.94    0.0 (0.0--2.63)
  **No GUD**                    7/2,653       0.26     16/2,570.5   0.64   0.42 (0.17--1.03)

95% CI based on an exact test when cell size was \<5 observations.

Because these findings were contrary to those reported in the South African trial, which observed circumcision efficacy against HIV acquisition irrespective of HSV-2 serostatus [@pmed.1000187-SobngwiTambekou1], we conducted a sensitivity analysis confined to the age group enrolled in the South African trial (men aged 18--24 y), and using the same Kalon index value of ≥1.1 for HSV-2 seropositivity as was used in the South African study. Using these criteria, HIV incidence was 1.02/100 py (7/688.8 py) in the intervention arm and 2.04 (14/686.5 py) in the control arm (IRR = 0.50, 95% CI 0.20--1.23), which is compatible with the protective effect of circumcision among the HSV-2 positive men in the South African trial (0.37, 95% CI 0.09--1.55) [@pmed.1000187-SobngwiTambekou1].

HIV incidence was highest among HSV-2 seroconverters, particularly if they reported GUD symptoms, and the risk of HIV acquisition was lower but not statistically significant in circumcised compared to uncircumcised men who acquired HSV-2 (IRR = 0.56, 95% CI 0.19--1.57). The protective effects of circumcision against incident HIV was most pronounced and statistically significant in persistent HSV-2 negative men (IRR = 0.34, 95% CI 0.15--0.81). The numbers of HSV-2 negative men with GUD were too small to estimate efficacy. The adjusted incidence rate ratios (adjIRR) of HIV acquisition based on Poisson multiple regression, were 0.58 (95% CI 0.39--0.87) for circumcision, and 3.11 (95% CI 1.90--5.10) for GUD. Using persistent HSV-2 negative men as the referent category, the adjIRRs of HIV acquisition were 3.15 (95% CI 1.86--5.31) for enrollment HSV-2 positives, 4.81 (95% CI 2.62--8.84) for HSV-2 seroconverters, and 3.02 (95% CI 1.63--5.59) for men with indeterminate HSV-2 status. Previously married men were also at higher risk of HIV (adjIRR 2.42, 95% CI 1.28--4.56).

Using mediation analysis, the estimated proportion of the HIV incident effect of circumcision explained by the reduction in symptomatic GUD among the circumcised men was 11.2% (1−\[−0.5451/−0.6140\], with 95% CI 5.0--38.0. There were 3,413 men who were HSV-2 negative at enrollment, and among this subpopulation, the adjusted proportion of HIV incident infections estimated to be mediated via HSV-2 seroconversion was 8.6% (95% CI −1.2 to 77.7). The confidence intervals are wide due to small number of HSV-2 seroconversions, and this mediated proportion estimate was not statistically significant.

Based on the data in [Table 3](#pmed-1000187-t003){ref-type="table"}, HIV incidence among circumcised men reporting GUD symptoms was 2.89/100 py compared with asymptomatic circumcised men (0.70/100 py), and the IRR of HIV acquisition associated with GUD was 4.12. The AR of HIV acquisition due to GUD in circumcised men was 10.7% (95% CI −1.8 to −21.6). Similarly, among uncircumcised men, HIV incidence was 5.27/100 py in those with GUD symptoms compared with 1.18/100 py in those without symptoms (IRR = 4.47). The AR of HIV acquisition attributable to GUD in uncircumcised men was 18.1% (95% CI 6.8--27.9). Therefore, ulceration contributed to a higher risk of HIV acquisition in both uncircumcised participants and circumcised participants, but confidence intervals were wide and the ARs of GUD were not significantly different between the two arms (χ^2^, *p* = 0.34).

Similarly, we estimated the AR of HIV acquisition attributable to HSV-2 seroconversion (compared to HSV-2 persistent seronegative). In the intervention arm, the IRR of HIV acquisition relative to persistent HSV-2 seronegative men was 8.69 (2.26/0.26), and the estimate of AR was 36.9% (95% CI −1.7 to −60.8%). In the control arm, the comparable IRR was 5.26 (4.05/0.77), and the AR was 30.6% (95% CI 9.3--46.8%). This suggests that HSV-2 seroconversion was associated with increased risk of HIV acquisition in both the intervention and control arms, but the ARs between the two arms were not significantly different (*p* = 0.63). Similar AR estimates for HSV-2 infections prevalent at time of enrollment were: intervention arm 17.1%, 95% CI 24.3--44.7, and control arm 29.8%, 95% CI 7.1--46.9, *p* = 0.63.

Discussion {#s5}
==========

MC reduced symptomatic genital ulceration by 41%, and the protection against GUD was similar irrespective of HSV-2 status in this population ([Table 2](#pmed-1000187-t002){ref-type="table"}). We estimate that approximately 11.2% of the protection from HIV afforded by circumcision is mediated by the reduction of symptomatic GUD due to circumcision ([Table 3](#pmed-1000187-t003){ref-type="table"}). Thus, it is likely that the reduction in symptomatic GUD made only a modest contribution to the overall impact of circumcision on prevention of HIV infection.

The finding that circumcision reduced GUD in the men who remained HSV-2 seronegative throughout the trial to approximately the same degree that it reduced GUD in HSV-2 seropositive men ([Table 2](#pmed-1000187-t002){ref-type="table"}) suggests that circumcision primarily reduces the rate of nonherpetic ulceration. It is noteworthy that no STI pathogens were detected in approximately 60% of ulcer swabs tested by real-time PCR. Low rates of STI detection in ulcers have also been reported among STD clinic patients with symptomatic GUD [@pmed.1000187-Risbud1], suggesting that a substantial proportion of ulcers are not due to sexually transmitted organisms. It is possible that such non-STI ulcers are due to trauma with secondary infections by other pathogens. Such traumatic lesions may be more common in uncircumcised men because the foreskin is retracted over the shaft of the penis during intercourse and minor trauma, particularly to the frenulum, is thought to be common [@pmed.1000187-Szabo1]. Therefore, it is possible that circumcision protects men from GUD largely by preventing traumatic lesions.

We were surprised that circumcision did not significantly reduce HIV acquisition among men who had prevalent HSV-2 at enrollment, whereas the procedure was associated with lower HIV risk in other groups, including men with HSV-2 indeterminate status and (although not significantly) in seroconverters ([Table 3](#pmed-1000187-t003){ref-type="table"}). It is possible that our failure to observe a protective effect of circumcision in prevalent HSV-2 positive enrollees is due to chance since this was a post hoc subgroup analysis that was not specified in the protocol. Our finding is contrary to that reported from the South African circumcision trial that observed similar efficacy of circumcision for HIV prevention among HSV-2 seroprevalent and HSV-2 seronegative men [@pmed.1000187-SobngwiTambekou1],[@pmed.1000187-SobngwiTambekou2]. However, there were differences between the trials in the age of study participants (18--24 y in South Africa versus 15--49 y in Rakai), the definition of HSV-2 infection (Kalon index value of 1.1 in South Africa, compared to 1.5 in Rakai based on our prior studies [@pmed.1000187-Gamiel1]), and in HSV-2 prevalence (5.9% in the South African trial, 27.9% in Rakai). Sensitivity analyses of the Rakai data using the same age groups and HSV-2 diagnostic criteria as the South African trial indicated comparable and nonstatistically significant estimates of circumcision efficacy for HIV prevention (South Africa IRR = 0.37, 95% CI 0.09--1.55, Rakai IRR = 0.50, 95% CI 0.20--1.23). These young men were likely to have more recently acquired HSV-2, and thus potentially have active herpetic infection. Therefore, one potential explanation for the divergence of findings between the Ugandan and South African studies may be attenuated efficacy of MC for HIV prevention in older men with more chronic herpes infections, due to recruitment of CD4+ T cells and immature dendritic cells into areas of HSV-2 replication even months after resolution of lesions [@pmed.1000187-Gupta1],[@pmed.1000187-Zhu1]. This persistence of HIV receptor cells might explain why trials of HSV-2 suppressive therapy did not show efficacy for HIV prevention [@pmed.1000187-Celum1],[@pmed.1000187-WatsonJones1], and reinforces the need for circumcised men to maintain safe sex practices (e.g., condom use or partner reduction) to avoid infection with HIV or STIs.

There are limitations to this study---a secondary analysis of two randomized trials that had not been prespecified in the trial protocols. The analysis was constrained by small numbers of observation in some subgroups, resulting in imprecise estimates. To increase sample size, we pooled data from HIV-negative men in two parallel trials, and although trial-specific findings were similar, sample size constraints precluded many trial-specific subgroup analyses (unpublished data). Self-reported symptomatic GUD is subject to misclassification because respondents may fail to recognize an ulcer or fail to recall it at time of interview. Also, although men were asked about GUD symptoms in the preceding interval, they were not asked about the duration of symptoms or multiple episodes of ulceration, so severe recurrent ulcers are likely to be underestimated. It is noteworthy that the efficacy of circumcision for prevention of clinically observed GUD at time of a study visit (PRR = 0.44, 95% CI 0.32--0.61), was greater than the efficacy estimated from the period prevalence of self-reported symptoms (PRR = 0.59, 95% CI 0.50--0.69), suggesting that the latter may have been affected by misclassification because of misreporting of symptoms.

In summary, we found that genital ulceration played only a modest role in protection from HIV due to MC, and that the reduction in self-reported GUD was observed in HSV-2 seronegative men, suggesting that the ulcers prevented by circumcision are likely to be nonherpetic in origin. Thus, the evidence suggests that most of the reduction in HIV risk afforded by circumcision is attributable to removal of vulnerable foreskin tissue containing HIV target cells.
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